Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer, Allergan to combine in $160bn deal; merger scrapped due to tax law change

Executive Summary

In the largest merger in the health care industry to date, Pfizer Inc. will pay a whopping $160bn in stock--$363.63 per share (a 20% premium)--for Allergan PLC. Allergan shareholders will receive 11.3 shares in the combined entity for each of their shares. Pfizer stockholders can also choose to receive some cash instead of stock of the combined company, provided the total cash is between $6-12bn (if it's more or less than the two limits, the stock and cash elections will be prorated).
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Payment Includes Stock
    • Reverse Acquisition
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register